Every AXLRx Myasthenia Gravis report, across 9 report types and 3 markets. Each is scoped to your asset and verified to a live source.
Three novel mechanisms in 24 months — FcRn antagonists vs C5 inhibitors, and the AChR+ vs MuSK+ line that segments the market.
ICER priced efgartigimod's value at $18,300 to $28,400 a year, under half its ~$418,400 launch cost, and that gap is hardening into a three-tier FcRn-to-C5 step-edit across US commercial plans.
Neuromuscular-junction autoantibody biology, the AChR/MuSK/seronegative split, and the crisis burden that defines US gMG.
US gMG prevalence runs 100,000-200,000, but only 4,000-6,000 patients are on FcRn therapy today, and 1,200-2,100 of those remain inadequately controlled — the near-term opportunity is the funnel gap, not the epidemiology total.
A ~4,000-patient UK gMG treatment gap, NHS neuromuscular network diagnostics, and efgartigimod's June 2025 NICE rejection (TA1069) that leaves the access gap unresolved.
100,000-200,000 US gMG patients narrow to a 4,000-6,000 on-FcRn-therapy pool, and 1,200-2,100 of them remain inadequately controlled despite treatment.
12,000-15,000 UK gMG patients on the broader estimate, of whom ~4,000 have moderate-severe disease and 2,000-3,000 are refractory, with no NICE-recommended novel agent for any of them.
Efgartigimod reached GCC neurology centres via SFDA/MOH UAE registration in 2023 — but NPHC formulary criteria for the FcRn class don't yet exist, so pyridostigmine and steroids still treat 85%+ of patients.
6,000-10,000 GCC gMG patients on the epidemiology estimate, of whom 200-300 are refractory and fewer than 50 are currently on biologic therapy.
A 30-centre NHS neuromuscular network coordinated through Muscular Dystrophy UK, plus a 3,000-member Myasthenia Gravis Association UK patient registry, is the institutional signal this workbook sizes before any individual name enters it.
Just 8-10 to 10-15 neuromuscular neurologists across six named GCC referral centres manage 70-80% of confirmed generalised myasthenia gravis. That concentration is exactly what this workbook sizes before any individual name enters it.
Binding constraint: address FcRn-inadequate responders or claim a serostatus niche — efgartigimod sets both the clinical and ICER pricing bar.
NICE has never modelled a cost-per-QALY for a myasthenia gravis biologic. Eculizumab's appraisal (TA636) closed before a dossier was submitted; efgartigimod's (TA1069) closed on evidence gaps, not a quantified ICER breach. A new entrant inherits no reusable comparator or price benchmark from either.
The thyroid-disease diagnostic confounder, specialist neurologist concentration, and the FcRn antagonist access pathway across GCC neurology practice.
NICE's June 2025 rejection of efgartigimod (TA1069) leaves UK myasthenia gravis with no NICE-recommended novel agent — eculizumab's own appraisal (TA636) was withdrawn by the manufacturer in 2020 without a cost-effectiveness verdict, and the NHS IVIg cost-offset argument is now the strongest lever for a future resubmission.
Refractory gMG in GCC is a 200-300 patient market concentrated at fewer than 15 named neurologists — the constraint is building a specialist key-account relationship, not clinical proof.
Two UK gMG estimates disagree by 3-4x on purpose: a narrower moderate-severe subgroup of roughly 4,000 (MGA UK survey) sits inside a broader 12,000-15,000 total prevalence figure that also counts mild, well-controlled cases the narrower estimate excludes.
GCC gMG sizing treats the 6,000-10,000-patient disease-landscape prevalence estimate as the authoritative broad base, with a 200-300-patient refractory subgroup, fewer than 50 currently on a biologic, as the narrower actionable segment inside it, not a competing total.
Why generalised myasthenia gravis has no formal NPHC programme — efgartigimod access runs through private insurance (fastest, 1-4 weeks) or hospital pharmacy committees, with NPHC engagement targeted for 2025-2026.
Why NICE's terminated eculizumab appraisal for gMG remains the price precedent every new asset must clear, the 2,000-3,000 refractory patients with zero NICE-commissioned biologic option, and the IVIg-offset economics that make a launch viable.
ICER priced efgartigimod's value at $18,300-28,400 a year, under half its ~$418,400 assumed launch price, and that gap is hardening into a three-tier step-edit staircase across US commercial and Part B plans.
No novel biologic is yet NHS-commissioned for generalised MG. Eculizumab's manufacturer withdrew its 2020 NICE appraisal before a verdict, and NICE rejected efgartigimod outright in 2025 — leaving rozanolixizumab as the FcRn class's last untested NICE bid.
No UK gMG biologic has ever cleared NICE at any price. Eculizumab's manufacturer withdrew before submitting an ICER, and efgartigimod's June 2025 rejection means a future entrant's price ladder starts from zero precedent, not a benchmark.
GCC gMG has no single price. Efgartigimod costs SAR 300,000-600,000/yr through private VHI, a different figure through hospital pharmacy committees, and a third through NPHC exceptional access, with a unified formulary price still 12-18 months out.
AXLRx publishes Competitive Intelligence, Payer & HTA, Disease Landscape, Market Sizing Model, Patient Flow Model, KOL Mapping, Launch Readiness, HTA Strategy Model, and Pricing Strategy Model for Myasthenia Gravis. Each report is scoped to your asset, verified to a live source, and delivered in 72 hours.
Current Myasthenia Gravis coverage spans United States, United Kingdom, and GCC (Gulf). Additional markets can be commissioned against the same evidence standard.
Every figure is cited to a live source at the point of writing and re-checked in an independent audit pass. The latest Myasthenia Gravis reports were updated July 2026.